Comparative Pharmacology
Head-to-head clinical analysis: EMTRICITABINE RILPIVIRINE AND TENOFOVIR ALAFENAMIDE versus EMTRICITABINE RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRICITABINE RILPIVIRINE AND TENOFOVIR ALAFENAMIDE versus EMTRICITABINE RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE.
EMTRICITABINE, RILPIVIRINE, AND TENOFOVIR ALAFENAMIDE vs EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) that is phosphorylated to its active metabolite, emtricitabine triphosphate, which competes with the natural substrate deoxycytidine 5'-triphosphate and incorporates into viral DNA, causing chain termination. Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds to a hydrophobic pocket near the active site of reverse transcriptase, causing a conformational change that inhibits enzyme activity. Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor (NtRTI) that is converted intracellularly to tenofovir diphosphate, which competes with deoxyadenosine 5'-triphosphate and causes DNA chain termination.
Emtricitabine and tenofovir disoproxil fumarate are nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit HIV-1 reverse transcriptase by competing with natural substrates and causing chain termination after incorporation into viral DNA. Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds to a hydrophobic pocket near the active site of HIV-1 reverse transcriptase, causing allosteric inhibition and preventing RNA-dependent DNA polymerization.
One tablet (200 mg emtricitabine/25 mg rilpivirine/25 mg tenofovir alafenamide) orally once daily with a meal.
One tablet (200 mg emtricitabine/25 mg rilpivirine/300 mg tenofovir disoproxil fumarate) orally once daily with a meal.
None Documented
None Documented
Emtricitabine: 10 h; Rilpivirine: 45 h (range 41–55 h); Tenofovir alafenamide: 0.51 h (converted to tenofovir), tenofovir: 32–49 h.
Emtricitabine: terminal half-life ~10 hours (clinical context: supports once-daily dosing; prolonged in renal impairment). Rilpivirine: terminal half-life ~50 hours (clinical context: supports once-daily dosing; long half-life allows missed dose forgiveness). Tenofovir: terminal half-life ~17 hours (clinical context: supports once-daily dosing; prolonged in renal impairment).
Emtricitabine: 86% renal (glomerular filtration and active tubular secretion), 14% fecal; Rilpivirine: 85% fecal (unchanged and metabolites), 6.1% renal (0.03% unchanged); Tenofovir alafenamide: <1% renal (as tenofovir), 31.7% fecal (as tenofovir), 32% urine (as tenofovir; 18.2% as TAF and metabolites).
Emtricitabine: 86% excreted unchanged in urine via glomerular filtration and active tubular secretion; 14% as metabolites. Rilpivirine: ~85% fecal as unchanged drug (25%) and metabolites (60%); ~6% urinary. Tenofovir disoproxil fumarate: 70-80% excreted unchanged in urine via glomerular filtration and active tubular secretion.
Category A/B
Category A/B
NRTI
NRTI